{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:31:09Z","timestamp":1790487069563,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012330","name":"Okayama University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ejphar.2018.02.022","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T12:38:01Z","timestamp":1518784681000},"page":"28-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia"],"prefix":"10.1016","volume":"825","author":[{"given":"Kenta","family":"Yagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Sendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.02.022_bib1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.02.022_bib2","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.1158\/1078-0432.CCR-07-0844","volume":"13","author":"Branford","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2018.02.022_bib3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2404638","article-title":"Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells","volume":"21","author":"Brendel","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2018.02.022_bib4","first-page":"79","article-title":"Differential cytogenetic profile in advanced chronic myeloid leukemia with sequential lymphoblastic and myeloblastic blast crisis","volume":"2","author":"Calder\u00f3n-Cabrera","year":"2013","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.ejphar.2018.02.022_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl","volume":"183","author":"Carlesso","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2018.02.022_bib6","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2018.02.022_bib7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3324\/haematol.2012.067959","article-title":"Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements","volume":"98","author":"Chase","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ejphar.2018.02.022_bib8","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2018.02.022_bib9","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/pmic.201200444","article-title":"Identification of Annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cells","volume":"13","author":"Colavita","year":"2013","journal-title":"Proteomics"},{"key":"10.1016\/j.ejphar.2018.02.022_bib10","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2018.02.022_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2006.06161.x","article-title":"BCR-ABL activates STAT3 via JAK and MEK pathways in human cells","volume":"134","author":"Coppo","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2018.02.022_bib12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2018.02.022_bib13","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2018.02.022_bib14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.molonc.2010.06.001","article-title":"Targeting leukemic stem cells by breaking their dormancy","volume":"4","author":"Essers","year":"2010","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejphar.2018.02.022_bib15","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood-2012-02-406751","article-title":"ALDH marks leukemia stem cell","volume":"119","author":"Fleischman","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2018.02.022_bib16","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2018.02.022_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.21915","article-title":"Characterization of chronic myeloid leukemia stem cells","volume":"86","author":"Gerber","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2018.02.022_bib18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/protein\/15.9.727","article-title":"Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7","volume":"15","author":"Giordanetto","year":"2002","journal-title":"Protein Eng."},{"key":"10.1016\/j.ejphar.2018.02.022_bib19","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1535-7163.MCT-09-0168","article-title":"Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors","volume":"8","author":"Grosso","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejphar.2018.02.022_bib20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"Embo. Mol. Med."},{"key":"10.1016\/j.ejphar.2018.02.022_bib21","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2018.02.022_bib22","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/leu.2013.60","article-title":"Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2018.02.022_bib23","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1038\/onc.2008.8","article-title":"Bcr-Abl induces autocrine IGF-1 signaling","volume":"27","author":"Lakshmikuttyamma","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2018.02.022_bib24","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.107.124461","article-title":"Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors","volume":"322","author":"Lee","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.02.022_bib25","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop imatinib (STIM) trial","volume":"11","author":"M Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2018.02.022_bib26","doi-asserted-by":"crossref","first-page":"34413","DOI":"10.1038\/srep34413","article-title":"Photodynamic N-TiO2 Nanoparticle Treatment Induces Controlled ROS-mediated Autophagy and Terminal Differentiation of Leukemia Cells","volume":"6","author":"Moosavi","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2018.02.022_bib27","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.leukres.2011.12.002","article-title":"Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML","volume":"36","author":"Nair","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejphar.2018.02.022_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fonc.2012.00030","article-title":"Role of STAT3 in transformation and drug resistance in CML","volume":"2","author":"Nair","year":"2012","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2018.02.022_bib29","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1349-7006.2009.01365.x","article-title":"Contribution of BCR-ABL-independent activation of ERK1\/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells","volume":"101","author":"Nambu","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejphar.2018.02.022_bib30","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.4049\/jimmunol.1200310","article-title":"Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback","volume":"189","author":"Pattison","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2018.02.022_bib31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.leukres.2013.11.006","article-title":"Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia","volume":"38","author":"Quintarelli","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejphar.2018.02.022_bib32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2018.02.022_bib33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate--a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.02.022_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2018.02.022_bib35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2013.01.026","article-title":"Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence","volume":"23","author":"Takeishi","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2018.02.022_bib36","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","author":"Traer","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2018.02.022_bib37","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/blood-2013-02-485573","article-title":"JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1 + chronic myeloid leukemia","volume":"122","author":"Warsch","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2018.02.022_bib38","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm0901-1028","article-title":"The ABC transporter Bcrp1\/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype","volume":"7","author":"Zhou","year":"2001","journal-title":"Nat. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918301006?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918301006?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:04:40Z","timestamp":1762142680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918301006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":38,"alternative-id":["S0014299918301006"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.02.022","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}